Thanks, Operator. And thank you all for joining us. Our first quarter was a strong start to a pivotal year for our business. We're on track on all of our key metrics and business activities behind the numbers continue to be ahead of our plans. Our gross margins, in particular, strengthened faster than we projected, up almost 300 basis points over last quarter with non - GAAP gross margins of 37.1%. This was a key goal that we expected to reach mid-year and we got there in Q1. The progress on gross margins is important for three reasons. First, it reflects broad customer demand, so we can balance our mix. Second, it reflects the strength of the market itself, because higher margin specialty RFID devices are the fastest growing segment, driving growth as well as margin expansion. Third, it reflects the strength of our financial systems. We track gross margins on each customer order. This lets us optimize our business model while also supporting customer account development. We'll go into more details later, but I wanted to focus on gross margin because it reflects key factors, including demand strength, customer diversity, specialty RFID growth, and internal information visibility to manage our business model as we scale. Our other metrics for Q1 were also on or ahead of plan. Revenues in our premises business were up strongly 23% year-over-year. We again fulfilled every key customer demand despite the supply chain pressures we're all dealing with. Our Identity segment grew 7%, led by 13% year-over-year growth in RFID, on track over a high growth comparable quarter in Q1 2021 that grew almost 60% year-over-year. Now, more importantly, our backlog at the end of Q1 for shipments in Q2 is up 32% versus the year prior, giving us confidence that we're on target for our 2022 plan. Our unit volumes were 48 million units, up 20% versus Q1 2021. And our average unit prices in RFID expanded, up 16% sequentially. Overall, our revenues grew to $25.1 million, a record for our first quarter and up 13% versus Q1 of 2021. Our forward indicators grew strongly with total backlog up 24% year-over-year. Now, in addition to these growth metrics, our business model progressed while increasing gross margins, we held operating expenses tight, resulting in EBITDA and net income ahead of plan and solidly on track for the year. Behind the financial and operational aspects of our first quarter results, we continued our track record of 100% customer retention in RFID and our other growth drivers made strong progress. These include existing customer launches and expansion, new designing often with nonrecurring engineering, or NRE, and technology launches. Among existing customers, a wide range of customer use cases are growing strongly. These encompass several dozen customers in the $100,000 to million-dollar annual revenue range. So I'd like to highlight some of these with an additional perspective of gross margin on these products. In the healthcare and medical device category, projects for test kits and surgical accessories shipped to six different customers, all with margins of over 55% and a couple with margins over 70%. Wine bottle, gas bottle, and other intelligent tamper proved devices sold to five more customers, all with margins ranging from 40% to 60%. High-end authenticated consumables for robotic cleaners, printers and a couple of others with margins in the 40% to 55% range. So our wide base of smaller growing customers continue to expand with margin profiles that support our expanded margin expectations. Turning to our transformational RFID initiatives, each made progress. Both of our cannabis initiatives progressed. As expected, the U.S. is moving faster and we're now getting a very clear view of volume potential. We're delivering 50,000 units to TrueGreen for their retail pilot. The pilot is now formerly set for July with all the systems at the MSOs, data flows, infrastructure deployment, and training going on over the next 68 weeks. Our solutions expanded to include our specialized dual frequency RFID device and we're also doing all the converting and data encoding. This expands our margin by increasing our value-add and obviously expense our mode. Despite the scope expansion we're on track for four-week delivery cycle to support the retail pilot schedule. They've also begun roll out projections that give us more specific volume visibility. Now, you might recall that Cresco Labs bought Columbia Care, expanding our customers reached in the cannabis MSO market to 17 states. Discussions for pricing and allocations are in various stages across all 17 states and specific projected volumes in just the four states of Maryland, Virginia, Delaware, and Pennsylvania are about a 150 million units annually. This gives us our first bottoms-up look at potential volumes overall in state-by-state detail. And these states represent about 11% of the populations of the states where marijuana is legal for medicinal or recreational use. So that translates to a total U.S. cannabis market of about 1 to 1.5 billion units for our devices. Our customers cover 17 of the 33 states were cannabis is legal. So our specific opportunity with this customer is around 500 to 750 million units. Now, we know that's a lot of data, but it's the first U.S. volume data we've gotten directly from the companies in the market, talking directly to their customers, so we wanted to share it. Now, the cannabis program in Canada also is progressing with about 2,000 of our test units delivered an in-test production programmer tuning and converting is going well, including hologram inclusion in the finished product, which is a new Canada specific requirement we've incorporated. Now, we'd go into more details in Q&A, but this billion-plus unit program is moving as we expected. Our auto-injector project is still on track for 2022 ramp-up, with S scale volumes still projected ultimately to be in the 100 million unit range. We're continuing to work intellectual property agreements, which is fundamental for medical device companies. Also, the critical first 25% of the 20,000 unit pilot run have been delivered and signed-off, putting us on track for a 100,000 unit production pilot mid-summer. With this deeply engaged process underway, as you can probably tell, our relationship is very strong, creating a solid margin price and volume opportunity that's also on track. Turning to our devices for prescriptions for the visually impaired. Through our direct sales and partners, we've now got four pharmacy chains in various stages of pilots and deployments. Now, nobody's as far along as CVS, but the broad adoption is underway. As for CVS specifically, they're increasing their marketing push. I mentioned the joint award we've received and we expect another at RFID Journal Live! in a few weeks. This gives the solution more visibility and puts more pressure on more pharmacies to adopt our solution. Lastly, our largest mobile device customer has a new design ramping right now with higher volumes than we originally expected, over 10 million units of that design over the next six months. Most of their prior designs are continuing, resulting in more total demand than we had projected. So in addition to these transformational opportunities, we've got over two dozen nonrecurring engineering projects underway and finished about a half dozen in Q1. I won't go into all of them, but one with major volume potential that we completed in Q1 was for the world's largest multinational closing producer and retailer. We've designed a specialty tag for asset tracking in their stores using our best in industry RFID on Metal technology. This is now going into pilot in Austria and Germany. This also got a lot of help from our partnership with NXP. They routed a special wafer to us for development and the pilots really giving us a boost to hit the customers’ goals. With this progress in Q1 RFID is positioned as our main growth driver in 2022 with upside volumes in just a few accounts that can transform our business. Our premises business also had very strong results growing more than three times the industries growth rate. So what drove it and is it sustainable? In physical and converged security, we've always been strong in the federal market. Last year, we launched actions to strengthen our commercial presence, and this really paid off with Q1 Premises growth that's entirely driven by commercial markets. Securities become a priority for every business and institution, and our combination of high security and cost-effectiveness and complete solutions from a single vendor delivered growth and market share gains. With this strength in commercial markets established, we're in a solid position to continue to grow at a multiple of the industries rate as the seasonally strong federal cycle in the second and third calendar quarters drive growth in our federal state, local, and education markets. This gives us high confidence in our 20% to 25% growth expectations for premises in 2022. Hitting well in this range in the first quarter, which is always the seasonally toughest quarter, clearly has us on track for 2022. If our commercial market strength continues, on top of increasing federal budgets for security, we could see premises growth even above our initial expectations for 2022. In addition to technology leadership, our supply chain management became a real competitive advantage in Q1 across both RFID and premises. In premises, we're taking advantage of competitors’ shortages, especially HID and companies that use Mercury hardware. In RFID, our strong supply relationships give us an advantage, like the leading clothing producer that we're going to pilot with helped a lot by NXP supply support. Our engineering expertise also let us offer alternate solutions to customers, get them accepted, and bringing into market far faster than our competitors. The combination of these supply chain strategies lets us take share in both our segments. Now one last area we hit hard in Q1 is our technical and thought leadership in our industry. We've kept a fast pace of industry rewards, recognition, announcements, and engaging in the main discussion forums in the industry. In Q1 we got awards for our Eco tags, our Tag On Metal devices and I mentioned the aim joined towards the CVS. We also launched a podcast series called humans in tech. We've already got 15 episodes up with titles like cannabis quality control from farm to fingertip, IOT connected collectibles and consumables and securing area 51. So you get the idea. They give us a unique social media voice in our pretty technology - centric markets. And this really builds our reputation as the industry thought leader from mass adoption of RFID based IOT. So our RFID business is on track with our transformational projects moving along ahead of plan in some cases, and volume outlook is getting clearer as the programs progress. Demand is growing fastest for our specialty RFID devices, driving up margins and unit prices also faster than we expected. Design wins are growing with our increased technical sales and engineering teams and our marketing investments are driving even more opportunities that our expanded sales team is converting. Our production capacity continues to expand to meet the higher demand and our systems are in place to manage customer lifecycles as more and more customers and projects come into our revenue streams every month. In premises, we've proved our ability to take market share aggressively, growing at three times the market rate and winning in the commercial market, just as Securities’ getting more focus and budget allocation than ever. And just as the seasonally strong federal, state, and local government buying cycle ramps up. So before getting into the next quarter, and our outlook for 2022 and beyond, I'll turn the call over to Justin to review the financial highlights for the first quarter. Justin?